Today’s guest post comes from Bill Nolan, VP/GM of Access and Adherence at RxCrossroads by McKesson.
Bill discusses the proliferation of co-pay accumulators and the negative effects they can have on patients, particularly those with high-deductible health plans. He offers solutions that biopharma companies can embrace to mitigate the impact, including the adoption of patient-centric support.
To learn more, download McKesson’s white paper: The Impact of Accumulators on Co-pay Programs.
Read on for Bill’s insights.
Read more »
Source: Post feed
